Agenus' BOT+BAL Shows 21.2-Month Survival in MSS Colorectal Cancer, Peer-Reviewed Data Published
AGEN has more than doubled off its 52-week low of $2.71.
Summary
Agenus published mature Phase 1b results for botensilimab plus balstilimab in 123 heavily pretreated MSS metastatic colorectal cancer patients without active liver metastases. Median overall survival reached 21.2 months with a 33% three-year survival rate, versus 10-14 months for standard later-line therapies. Confirmed objective response rate was 21%, including three complete responses, and responses occurred even in tumors with low TMB and no PD-L1 expression. This peer-reviewed publication in Clinical Cancer Research adds biomarker evidence supporting BOT's Fc-enhanced immune-priming mechanism. The data strengthen the rationale for the planned Phase 3 ROBBIN trial in neoadjuvant MSS colon cancer, which is funded by the recent $85M private placement. No new safety signals were reported, and immune-mediated colitis resolved in 98% of affected patients.
At the time of this announcement, AGEN was trading at $7.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $353.4M. The 52-week trading range was $2.71 to $8.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.